FloBio LLC

FloBio is pioneering a novel point of care (POC) blood diagnostic platform that assesses blood biology and clotting status under physiologic, dynamic flow. Our proprietary microfluidic technology is designed to set a new standard for monitoring blood function in emergency critical care settings. Rapid and real-time measurements precisely identify the clotting defects, enabling clinicians to personalize management of bleeding and thrombotic risk. The results is fewer complications, improved clinical outcomes and reduced health care costs. Problem Early identification and corrective treatment of clotting defects is necessary for effective management of bleeding and thrombotic risk in emergency, critical care settings. Bleeding and clotting deficiencies are major contributing factors to the 5 million trauma injury fatalities worldwide. In addition, with over 5 million DOAC patients in the US, there are a growing number of patients finding themselves in emergent situations and at risk for or experiencing major bleeds. Current tests such as lab based clotting tests and emerging point of care viscoelastic tests are time consuming and provide limited information to physicians who need to quickly make treatment decisions based on clotting function. In some cases there can be an inability or delay in personalized treatment and correction of the clotting defect. This can lead to increased patient risk, greater exposure to transfusion or blood products, complications, long-term disability and mortality. FloBio offers a microfluidic based technology built upon innovations in device manufacturing and multiplex analysis of blood hemodynamics and clotting metrics. The FloBio diagnostic system utilizes dynamic blood flow to rapidly and accurately identify clotting deficiencies, providing clinicians with comprehensive and actionable information to personalize treatment.

• Employees 4
• Founded 2017